[A case of drug induced pneumonitis caused by oral etoposide].
We report a case of drug induced pneumonitis caused by oral etoposide. A 63-year-old man was admitted to our hospital in August 1991 because of low grade fever and dyspnea. He underwent right upper lobectomy on Nov. 27th, 1990 for lung cancer (squamous cell carcinoma), and courses of adjuvant chemotherapy (CBDCA, IFX, etoposide) during the following admission period. He was discharged on Feb. 14th, 1991, and as an outpatient, oral etoposide (25 mg/day) was administered for about 7 months (6,125 mg in total). Chest X-ray film on admission showed reticulonodular shadows in bilateral lung fields, and computed tomography showed diffuse interstitial shadows. Blood gas analysis showed marked hypoxemia (PaO2 breathing room air was 48.4 Torr). Transbronchial lung biopsy revealed edema of the alveolar walls and marked proliferation of type II alveolar epithelial cells, suggesting cytotoxic reaction. After termination of etoposide administration and following steroid pulse therapy, both clinical symptoms and hypoxemia were ameliorated. To our knowledge, this is the first report of etoposide-induced pneumonitis.
Araki
N
N
Second Department of Internal Medicine, Nagoya University, School of Medicine, Japan.
Matsumoto
K
K
Ikuta
N
N
Ando
M
M
Taki
F
F
Suzuki
R
R
Takagi
K
K
D000284:Administration, Oral; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000139:chemically induced*
D005047:Etoposide